Laurus Labs Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
LAURUSLABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.1 pts more than Nifty Midcap 150 and 1.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Laurus Labs reported strong consolidated revenue from operations of ₹1,569.57 crores for Q1 FY26, up 31.4% from ₹1,194.91 crores in Q1 FY25. Profit before tax jumped sharply to ₹224.22 crores from ₹18.46 crores, while net profit after tax surged to ₹161.08 crores from just ₹12.21 crores a year ago, marking a low-base recovery. Standalone revenue grew 28.3% YoY to ₹1,432.75 crores with standalone PAT of ₹157.94 crores (vs ₹28.78 crores). Basic and diluted EPS stood at ₹3.02 on a consolidated basis. The statutory auditors Deloitte Haskins & Sells LLP issued an unmodified limited review conclusion. The company also invested ₹40 crores in subsidiary Laurus Bio and allotted 572,408 shares under its ESOP scheme during the quarter.
The sharp YoY recovery in revenue and profits should be viewed positively by shareholders, though the unusually low base in Q1 FY25 makes the growth optic stronger than it is. Investors should watch whether the strong margin trajectory sustains in upcoming quarters, as QoQ revenue dipped 8.8% from Q4 FY25.